+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07629258

First-in-Human Study Evaluating Safety and Effects of GW01-200 Tablets in Adults with Advanced Tumors

Led by Groovy Medicine (Hangzhou) Ltd. · Updated on 2026-08-14

100

Participants Needed

3

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying GW01-200 tablets in a phase 1, open-label trial to assess their safety, tolerability, pharmacokinetics, and preliminary effectiveness in adults with advanced tumors, including both solid tumors and blood cancers. The study focuses on participants whose disease has progressed after standard treatments or who have no available standard treatments. Participants receive GW01-200 tablets orally at increasing dose levels to find the recommended dose for further study. The trial includes several parts where participants with advanced solid tumors or relapsedrefractory hematological malignancies are treated with specified doses to monitor effects and responses. During the study, participants will undergo assessments of adverse events, drug concentration in the body, and tumor response over up to approximately 2 years. Researchers will monitor safety, preliminary treatment effects, and pharmacokinetic properties through regular evaluations and follow-ups throughout the trial duration.

CONDITIONS

Brief Title

A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors

Research Team

Y

Yongchao Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here